Rechercher dans ce blog

Friday, January 28, 2022

COVID-19: NACI updates guidance on primary vaccines, booster shots for children and adolescents | Watch News Videos Online - Globalnews.ca

Dr. Theresa Tam, Canada’s chief public health officer, said Friday that the National Advisory Committee on Immunization (NACI) has provided updated guidance on booster shots for children aged five to 11 and for adolescents aged 12-17. NACI now strongly recommends that children ages five to 11 years receive a complete dose of the primary series of the Pfizer ten microgram pediatric MRNA COVID-19 vaccine with at least eight weeks between the first and second dose. NACI is also recommending a third dose for moderately to severely immunocompromised children in the age group.

Adblock test (Why?)


COVID-19: NACI updates guidance on primary vaccines, booster shots for children and adolescents | Watch News Videos Online - Globalnews.ca
Read More

Thursday, January 27, 2022

55% of Sea to Sky's kids have had their first COVID-19 shot: BCCDC - Squamish Chief

As of Jan. 25, 95% of adults in the Howe Sound region have received their second dose of a COVID-19 vaccine, while 36% have received a booster shot. 

Provincially, it is Glacier Media's calculation that 86.8% of B.C.'s total population has had at least one dose of vaccine, and 81% of the province's total population has had two doses. Almost 38% have had their booster doses.

Back in our Howe Sound region, among children aged five to 11 years old, 55% have received a first pediatric vaccine, while according to the BC Centre for Disease Control, none in our region have received a second dose. 

Other regions, such as in Vancouver, are beginning to clock second pediatric doses.

As of the end of December, Howe Sound has tallied 4,199 cases of COVID-19 since the start of the pandemic. 

For the week of Jan. 16 to 22, the region clocked 77 positive cases.

BC Centre for Disease Control notes that due to changes in testing strategies in B.C. driven by the Omicron variant, case counts are likely an underestimate of the true number of COVID-19 cases. 

In December, when testing centres across B.C. — Squamish included — were overwhelmed with patients, provincial health officer Dr. Bonnie Henry told vaccinated people with mild illnesses to self-isolate and not get tested.

On Jan. 26, 949 people were in hospital in B.C. with COVID-19. 

Of those,136 are in intensive care units (ICUs).

Vancouver Coastal Health vaccination clinics for COVID-19 are being held at the Sea To Sky Hotel on Jan.  31; and through February on Feb. 1, 2, 7 to 9, and 14 to 16. These clinics run from 10 a.m. until 1 p.m. and again from 2 p.m. to 6 p.m. 

Go here to register or for more information. 

~With files from Glen Korstrom/Glacier Media

Adblock test (Why?)


55% of Sea to Sky's kids have had their first COVID-19 shot: BCCDC - Squamish Chief
Read More

Wednesday, January 26, 2022

NACI Strengthens Guidance on Pediatric Vaccines for Children 5 to 11 - VOCM

The country’s Chief Public Health Officer says Canada’s National Advisory Committee on Immunization is strengthening its recommendations on pediatric vaccine for children aged 5 to 11 years.

Newfoundland and Labrador has some of the highest pediatric vaccination rates in the country, but concerns are being expressed about lower rates in other jurisdictions.

Dr. Theresa Tam says NACI strongly recommends that children 5 to 11 receive two doses of the pediatric vaccine, at least eight weeks apart, with a third dose recommended for moderately to severely immunocompromised children.

She says although numbers are starting to decline, COVID infection rates remain high across all age groups in Canada, including children 5 to 11.

Dr. Tam says despite evidence that children remain at low risk of severe illness, higher infection rates mean more children are being hospitalized. Children can also develop a rare, but serious, multisystem inflammatory syndrome, sometimes occurring several weeks after infection.

Adblock test (Why?)


NACI Strengthens Guidance on Pediatric Vaccines for Children 5 to 11 - VOCM
Read More

COVID wastewater data shows decline in St. Louis region - KMOV St. Louis

Adblock test (Why?)


COVID wastewater data shows decline in St. Louis region - KMOV St. Louis
Read More

Tuesday, January 25, 2022

COVID-19: N.S. reports 5 deaths, 92 in hospital (Jan 25) - 101.5 The Hawk

Nova Scotia is reporting 11 new hospital admissions and nine discharges.

Meantime, there five deaths related to the virus for the second straight day.

— a woman in her 70s in Central Zone

— a man in his 80s in Central Zone

— a man in his 80s in Central Zone

— a man in his 80s in Central Zone

— a woman in her 80s in Eastern Zone.

“Today we lost five more Nova Scotians to this virus, and I offer my deepest condolences to those who are grieving the loss of a loved one,” said Premier Tim Houston. “This virus has taken a lot from us, but we must stay vigilant. We need to slow down our activities, get vaccinated when we can whether that’s a first, second or booster dose and strictly follow the public health measures in place. Our actions will protect ourselves and each other.”

There are 92 people in hospital who were admitted due to COVID-19 and are receiving specialized care in a COVID-19 designated unit. That includes 15 people in ICU. The age range of those in hospital is 0-100 years old. The average age is 68, and the average length of stay of people admitted to hospital due to COVID-19 is seven days.

“This is another very sad day and I send my sympathies to the loved ones of the five Nova Scotians who died,” said Dr. Robert Strang, Nova Scotia’s Chief Medical Officer of Health. “This has been a difficult two years for all Nova Scotians. I continue to ask for people’s patience, understanding and cooperation. Please respect the public health restrictions and get vaccinated to help slow the spread of this virus.”

Of the 92 people in hospital, 89 were admitted during the Omicron wave.

The vaccination status of those in hospital is:

— 17 (18.5 per cent) people have had a third dose of COVID-19 vaccine

— 55 (59.8 per cent) are fully vaccinated (two doses)

— 3 (3.3 per cent) are partially vaccinated

— 17 (18.5 per cent) are unvaccinated.

It is important to note that less than 10 per cent of Nova Scotians are unvaccinated.

There are also two other groups of people in hospital related to COVID-19:

— 92 people who were identified as positive upon arrival at hospital but were admitted for another medical reason, or were admitted for COVID-19 but no longer require specialized care

— 120 people who contracted COVID-19 after being admitted to hospital.

Vaccine Coverage:

As of January 24, 2,048,961 doses of COVID-19 vaccine have been administered. Of those, 90.9 per cent of Nova Scotians have received their first dose, and 83.3 per cent have received their second dose.

As well, 46.8 per cent of Nova Scotians 18 and older have received a booster dose, and 9.6 per cent have booked a booster dose appointment.

Cases and Testing

There are 234 cases in Central Zone, 62 cases in Eastern Zone, 80 cases in Northern Zone and 116 cases in Western Zone.

There are an estimated 4,250 active cases of COVID-19 in Nova Scotia.

Long-Term Care Outbreaks:

The Province is reporting two outbreaks in long-term care facilities:

–two residents and one staff member at Villa Acadienne in Meteghan –two staff members at My Cape Breton Home for Seniors (Westmount) in Cape Breton Regional Municipality.

Public health is working with the facilities to prevent further spread. Increased public health measures and restrictions are in place.

Adblock test (Why?)


COVID-19: N.S. reports 5 deaths, 92 in hospital (Jan 25) - 101.5 The Hawk
Read More

Neighborhoods play role in older adults' pandemic experience | The University Record - The University Record

How have older adults adjusted to living under the pandemic? There’s no one-size-fits-all experience, according to University of Michigan researchers.

READ THE STUDY

In spring and summer 2020, U-M researchers Jessica Finlay and Lindsay Kobayashi launched a study to examine how the COVID-19 pandemic has fundamentally changed neighborhood environments and the way older adults age in place.

They found that some older adults reported less social interaction and diminished relationships with their neighbors, while others reported more. Some older adults experienced less social support from their neighbors, while others felt they experienced more support from their neighbors.

Some people’s neighborhoods became totally quiet during the pandemic, while other neighborhoods bloomed with outside happy hours, children playing in front yards, and residents walking and biking in the neighborhood — so much so that some study participants complained about the noise.

“There’s not one model of experience for older adults in this pandemic,” said Finlay, the study’s lead author and a postdoctoral researcher at the Institute for Social Research. “There’s a whole diversity of reactions and experiences and perceptions going on across the country that I think reflects some of the broader disparities, polarization and inequities that exist across the entire fabric of the United States.”

Their results are published in The Gerontologist.

To examine how older adults are living under the pandemic, Finlay and her fellow researchers recruited 6,886 participants to complete an online survey in April and May 2020. The participants, who were from across the country, including Alaska, Hawaii and Puerto Rico, then completed monthly follow-up surveys.

These surveys assessed the participants’ physical and mental health, level of socialization and health behaviors such as exercise and drinking, as well as COVID-19 testing and symptoms. The survey also included open-ended questions to gather responses about participants’ ongoing experiences, perspectives and significant life events.

From this group of respondents, the researchers drew a random sample of 1,000 open-ended responses. They used quotas for age, gender, race, ethnicity and education aiming to match the U.S. population of those over the age of 55. Most of the participants lived in neighborhoods; about 20 percent of the respondents said they did not.

More than 25 percent of the study participants reported reduced quality and quantity of interactions with their neighbors — especially impromptu run-ins on front steps, porches or yards — and a stop to gatherings such as indoor happy hours, book clubs and athletic activities.

They thought that COVID exacerbated isolation, particularly among those without access to outdoor gathering spaces. Ideological and cultural differences prompted feelings of isolation, and those who lived in neighborhoods with high rates of COVID-19 cases or public health misinformation more often shared feeling isolated. But 12 percent of participants reported more neighborly interactions and socializations.

“I now know the names of my neighbors and we talk across the street from each other. On my morning walk, I normally see 15-25 other walkers and we keep our distance, wave and say hi,” one participant said.

Some participants reported less psychosocial support.

“One of my neighbors is in ‘comfort care’ hospice and I feel extremely bad that I can’t go sit with her, bring them meals, etc., due to COVID concerns,” another participant said.

Other participants who moved during the pandemic reported feeling isolated because they weren’t able to get to know their new neighbors. Some participants reported witnessing how COVID and varying adherence to public health measures — for example, mask-wearing and social distancing — seemed to underscore the country’s political divisions.

Some of the study participants worried that local restaurants and shops where they previously gathered for a cup of coffee and social interaction — locations Finlay calls “third places” outside of home and work — were going out of business. And still other people’s experiences were affected by neighborhood conditions.

“We know neighborhoods are starkly different,” Finlay said. “Not everyone has access to places to engage with each other and enjoy each other’s company. Having parks or big front porches are often skewed more toward affluent areas, which are predominantly where older white adults live. In comparison, communities of color often have less access to these private spaces to safely engage during COVID.”

The researchers noticed those who experienced decreased engagement, socialization and support levels were more commonly participants of color.

“We also know that COVID numbers are not equal among our communities, too. So our hardest hit communities are often lower income and underserved,” Finlay said. “It just speaks to needing deep policy changes and structural investment in certain communities.”

This kind of attention to neighborhood infrastructure is critical to help older adults age well in place, the researchers say. Specifically, the COVID-19 pandemic may have underscored how important neighborhoods are to the health and well-being of older adults — accessible neighborhoods critically influence the ability of older adults to feel safe and supported, and to be physically and socially active, Finlay said.

“It is important to identify and address the pandemic’s long-term implications for aging in place, such as how older adults can safely inhabit public neighborhood spaces, adjust to being in crowded areas without feeling anxious, and return to the ‘new normal’ of daily life,” she said.

Tags:

Adblock test (Why?)


Neighborhoods play role in older adults' pandemic experience | The University Record - The University Record
Read More

Pfizer anti-COVID pill's dangerous interaction with common drugs will narrow its benefit, experts say - National Post

A component of Paxlovid can interact dangerously with a slew medications, pumping up the potency of blood thinners, heart-arrhythmia therapies, epilepsy drugs and others

Article content

The sense of excitement generated by Health Canada’s approval last week of a promising new drug to treat COVID infections was best embodied by Ontario Premier Doug Ford.

Advertisement

Article content

Pfizer’s Paxlovid not only appeared to cut hospitalizations by 89 per cent in high-risk patients given the drug early in their illness, it had the convenience of being an oral medication. The federal government ordered a million courses of it — about $670 million dollars worth .

“Great news,” Ford enthused on Twitter when it got the regulatory green light .

Article content

But the buzz around Paxlovid has largely obscured one major downside of the pill. A booster added to the drug can interact dangerously with a slew of commonly used medications, pumping up the potency of blood thinners, heart-arrhythmia therapies, epilepsy drugs and others.

And the patients targeted for its use – those most at risk of serious COVID disease because of age and other health issues – are also the people most likely to be taking those “contraindicated” medications.

Advertisement

Article content

In some cases the interactions could be managed, but it’s clear the problem will limit the pool of potential recipients, experts say.

“It has a utility, it has a use,” said Dr. Gerald Evans, head of the infectious diseases division of the Queen’s University medical school. “(But) I certainly would not call it a game-changer.”

Article content

  1. Boxes of Pfizer Inc.’s Paxlovid antiviral medication arranged in a warehouse in Shoham, Israel, on Jan. 18, 2022

    First shipment of COVID-19 antiviral pill on its way across Canada: Trudeau

  2. Pfizer’s antiviral treatment for COVID-19 is approved for adult patients with mild or moderate symptoms at high risk of becoming more seriously ill.

    Health Canada approves Pfizer anti-viral pill for treatment of COVID-19

Pfizer spokeswoman Christina Antoniou downplayed the scope of the challenges, noting that patients will be taking Paxlovid for a relatively short period of time and that it contains a low dose of the booster ingredient.

“We believe that healthcare professionals should find most drug-to-drug interactions to be generally manageable,” she said.

Advertisement

Article content

Finding an effective, easy-to-use treatment for COVID has been a challenge, the available medications either having modest benefit or requiring significant health-care resources to administer.

Paxlovid seemed to combine the convenience of a take-at-home pill with significant efficacy; Pfizer’s EPIC-HR trial reported that it reduced the chances of high-risk patients ending up in hospital by almost 90 per cent.

But one part of the medication is a drug called ritonavir, which inhibits enzymes that metabolize drugs, leaving behind more of the active ingredient, nirmatrelvir, so it works more powerfully against the virus.

The catch? The ritonavir booster has the same impact on a range of other drugs, increasing their potency to a potentially dangerous level in some cases.

Advertisement

Article content

A patient on blood thinners could end up with spontaneous bleeding in the gastrointestinal tract or brain, noted Evans. Someone taking pills for hypertension might see their blood pressure fall so much they pass out, said Dr. Andrew Hill, a pharmacology researcher at the U.K.’s Liverpool University.

“There are all kinds of ways that Paxlovid could cause serious harm,” he said.

Ritonavir is used in HIV treatments, too, so there is a wealth of knowledge about those conflicts. The U.S. Food and Drug Administration (FDA) product monograph for Paxlovid lists over 100 drugs that it says should not be taken with the COVID pills or whose use ought to be carefully monitored.

With certain anti-arrhythmia drugs, for instance, it could actually cause heart rhythm problems and is contraindicated, the FDA cautions. Combining Paxlovid with the cholesterol-lowering pills lovastatin and simvastatin has the potential to lead to rhabdomyolysis, a potentially life-threatening breakdown of skeletal muscle fibres. A drug used to treat enlarged prostates could cause dangerously low blood pressure if taken with Paxlovid.

Advertisement

Article content

“People are assuming that if they get COVID and they have risk factors, they can just get this prescription. But it’s not that simple,” said Dr. Lynora Saxinger, a University of Alberta infectious-disease specialist. “It is a great thing to have in the tool box, but won’t make a huge dent.”

Doctors will have to carefully assess patients and in some cases could reduce the dose of a particular contraindicated drug or stop its use over the five-day course of Paxlovid, said Evans. In other situations, doing so would be too risky for the patient, he said.

Such assessments will be challenging with elderly patients who in some cases are taking multiple medications but might not recall the importance of each one, said Dr. Zain Chagla, an infectious-disease specialist and McMaster University professor

Advertisement

Article content

“It’s going to be difficult in places like long-term care homes, where medication lists are really, really long and you don’t know why they’re taking them in some cases,” he said.

Despite the challenges surrounding drug-to-drug interactions, however, infectious-disease specialists say Paxlovid will still find a niche of patients. And where the Pfizer drug is not appropriate, other treatments are becoming available, noted Chagla.

He runs Canada’s first clinic to treat COVID patients with monoclonal antibody drugs and estimates that dozens have been prevented from ending up in hospital.

Although the Canadian government has not divulged how much it is paying for Paxlovid, Pfizer indicated the U.S. bought its initial supply for $530 per course .

A just-released McGill University study suggests paying such steep prices may still be cost-effective, on top of the health benefits. It looked at the cost of using various drugs to prevent COVID hospitalizations and concluded that most were cheaper than having to treat the patient in hospital.

• Email: tblackwell@postmedia.com | Twitter:

Advertisement

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Adblock test (Why?)


Pfizer anti-COVID pill's dangerous interaction with common drugs will narrow its benefit, experts say - National Post
Read More

The Winnipeg Foundation Innovation Fund supports cutting-edge projects - UM Today

February 1, 2024 —  Three interdisciplinary teams from the Rady Faculty of Health Sciences have received $100,000 grants from The Winnipeg...